A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study) A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)

A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)

Pratima Chowdary, M.D., presented Phase I/II safety and efficacy results on FLT180a in hemophilia B (HB) patients. FLT180a is an investigational gene therapy medicinal product candidate that includes AAVS3, a rationally designed capsid designed to deliver higher levels of liver transduction than wild-type adeno-associated virus (AAV), and a codon optimized F9 gene with a gain-of-function mutation.
Read more
Higher Incidence of Thrombotic Complications in Hospitalized Patients With SARS-COV-2 Virus Versus Influenza Virus Infections Higher Incidence of Thrombotic Complications in Hospitalized Patients With SARS-COV-2 Virus Versus Influenza Virus Infections

Higher Incidence of Thrombotic Complications in Hospitalized Patients With SARS-COV-2 Virus Versus Influenza Virus Infections

Studies reported findings of coagulopathy and high incidences of thrombotic complications in hospitalized patients with COVID-19 pneumonia in patients admitted to the intensive care unit (ICU) but, to a lesser extent, also in ward-admitted patients. What is unknown is how the incidence of thrombotic complications in COVID-19 patients compares with that observed in hospitalized patients with other virus infections, including influenza, as some studies suggest that SARS-CoV-2 itself induces a specific procoagulant effect.
Read more
Incidence of Venous Thromboembolism in Patients Discharged After COVID-19 Hospitalisation Incidence of Venous Thromboembolism in Patients Discharged After COVID-19 Hospitalisation

Incidence of Venous Thromboembolism in Patients Discharged After COVID-19 Hospitalisation

Matthias M. Engelen of University Hospitals Leuven in Leuven, Belgium, presented late-breaking results evaluating the residual thrombotic risk and incidence of venous thromboembolism (VTE) in patients following hospitalization for COVID-19.
Read more
RSS
1234